Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
Mr. Dorman and Dr. Lockshin both bring significant industry experience that will be instrumental to supporting RXi’s growth and development initiatives.

Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry with Johnson & Johnson and Baxter, in various leadership roles, to RXi. He currently serves as Chairman and CEO of DFB Pharmaceuticals, a Fort Worth, TX based holding company that, over the last 20 years, has successfully invested in and operated multiple pharmaceutical businesses. In that role, he acquired several companies, three of which were turned around to profitability, from Chapter 11 status at acquisition, and later sold to a large, multi-national, public corporation. He holds a Bachelor of Science degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University. “Mr. Dorman is one of the remarkable icons in the healthcare industry and we are thrilled to have him join our Board,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, “Paul’s experience and network in both the large and small pharma world, as well as his wisdom in leading companies to success, will be major contributing factors to the RXi Board of Directors and the growth of our Company.”

Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. Most recently, he has been an Independent Pharmaceutical & Life Sciences Consultant for OPKO Health, Inc. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO's R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. “Dr. Lockshin has an impressive career track record in research and development of new drugs”, commented Dr. Geert Cauwenbergh. “With RXi Pharmaceuticals in the midst of a game changing drug in development with RXI-109 for dermal scarring, Curt will provide valuable insights into the development of our drugs. With Paul Dorman and Curt Lockshin joining our current Board members Bob Bitterman and Keith Brownlie, RXi Pharmaceuticals has a well rounded Board of Directors with an appropriate balance of all key elements needed for success.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promising New Data on Self-delivering RNAi Compounds
RXi Pharmaceuticals Corporation have presented new data, on the company's proprietary self-delivering RNAi compounds developed to target Tyrosinase (TYR) and Collagenase (MMP1).
Wednesday, May 13, 2015
RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement
Agreement for RXI-109 in the European Union under the “Specials” Provision.
Tuesday, November 19, 2013
RXi Pharmaceuticals Awarded NCI SBIR Funding
Company awarded approximately $300,000 to advance self-delivering RNAi technology.
Friday, October 12, 2012
RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs
The collaboration will evaluate the potential utility of RXi’s rxRNA™ technology against specific miRNA targets of interest to mirage.
Tuesday, April 13, 2010
RXi Acquires Exclusive License to Potentially Paradigm-Changing RNAi Delivery Technology from Advirna LLC
The in-licensed technologies encompass four distinct approaches, with the primary focus on “self-delivery” of RNAi therapeutics.
Wednesday, July 29, 2009
RXi Pharmaceuticals Presented Breakthrough RNAi Delivery Technologies at the TIDES® 2009 Conference
Company’s CSO, Anastasia Khvorova, presented new pre-clinical data on therapeutically advanced RNAi compounds and delivery technologies.
Monday, May 25, 2009
RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts
Company plans to advance the discovery and development Oral rxRNA™ therapeutics for inflammatory diseases.
Wednesday, February 11, 2009
RXi Pharmaceuticals Licenses RNA Chemistry Technologies from TriLink Biotechnologies
The agreement includes rights to sublicense a patented RNA linker technology, a patent application on RNAi compositions and an undisclosed chemistry approach.
Tuesday, September 11, 2007
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos